Jeffrey S. Weber, MD, PhD, looks ahead to the upcoming ASCO conference, in which he anticipates a convergence of updates on previously published studies — studies that collectively produced a necessary "plateau" or consolidation of data and generated successive investigations that have, in turn, produced new elevations.
Whether the topic is advances on neoadjuvant regimens, the latest data on survival outcomes in the RELATIVITY-047 study, the viability of treating kidney transplant patients with blockade inhibitors, or the possibilities surrounding combinations with a PD-L1 blockade, the gathering of new information guarantees a good sample of positive progress in the field of melanoma.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Approaching ASCO 2022: Reaching New Plateaus in the Treatment of Melanoma - Medscape - May 26, 2022.